Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

(European Society for Medical Oncology) Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

https://www.eurekalert.org/pub_releases/2018-10/esfm-tsg102018.php

Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news